MIN-102

DRUG3 trials

Sponsors

Minoryx Therapeutics, S.L.

Conditions

AdrenoleukodystrophyCerebral AdrenoleukodystrophyFriedreich Ataxia

Phase 2

A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.

CompletedNCT03231878

Minoryx Therapeutics, S.L.Adrenoleukodystrophy

Start: 2017-12-08End: 2025-03-06Updated: 2025-03-18

A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients

CompletedNCT03917225

Minoryx Therapeutics, S.L.Friedreich Ataxia

Start: 2019-03-26End: 2020-09-14Updated: 2022-10-13

A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT)

Minoryx Therapeutics, S.L.Cerebral Adrenoleukodystrophy

Start: 2019-09-13End: 2023-12-31Target: 13Updated: 2023-07-18

Related Papers

Safety and efficacy of leriglitazone in childhood cerebral adrenoleukodystrophy (NEXUS): an interim analysis of an open-label, phase 2/3 trial.

2025-05-243 citations

Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2-3 trial.

2023-02-0128 citations

Efficacy and Safety of Leriglitazone in Patients With Friedreich Ataxia: A Phase 2 Double-Blind, Randomized Controlled Trial (FRAMES).

2022-11-0122 citations